Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hormones and Bone Tissue

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The 5-year outcomes and predictors of healing in chronic anal fissure treated with botulinum toxin: a retrospective analysis of 199 cases.

Techniques in coloproctology·2025

Same author

Splenic flexure mobilization: does body topography matter?

Techniques in coloproctology·2024

Same author

The impact of plasma-rich platelet injection to perianal sphincters on incontinence and quality of life in patients with rectal cancer after low anterior or intersphincteric resection: a prospective cohort study.

Techniques in coloproctology·2024

Same author

Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration.

Journal of endocrinological investigation·2024

Same author

Effects of thymoquinone in the lungs of rats against radiation-induced oxidative stress.

European review for medical and pharmacological sciences·2024

Same author

Increased SOCS1 and SOCS3 expression in papillary thyroid carcinoma and its association with prognosis.

European review for medical and pharmacological sciences·2023

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

Rapid Quantification of Oxidized and Reduced Forms of Glutathione Using Ortho -phthalaldehyde in Cultured Mammalian Cells In Vitro

Rapid Quantification of Oxidized and Reduced Forms of Glutathione Using Ortho -phthalaldehyde in Cultured Mammalian Cells In Vitro

Published on: June 28, 2024

THE EFFECT OF ANTITHYROID DRUGS ON OSTEOPONTIN AND OXIDATIVE STRESS IN GRAVES' DISEASE.

M Kocak¹, E Akarsu², H Korkmaz³

¹Pazarcik State Hospital, Internal Medicine, Kahramanmaras, Turkey.

Acta Endocrinologica (Bucharest, Romania : 2005)

|September 12, 2019

Summary

This summary is machine-generated.

Propylthiouracil (PTU) is more effective than methimazole (MTZ) in reducing osteopontin and oxidative stress in Graves' disease patients. Both treatments aimed to restore euthyroid state, but PTU showed superior outcomes in managing these specific biomarkers.

Keywords:

Graves’ disease methimazole osteopontin oxidative stress propylthiouracil

More Related Videos

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jun 29, 2026

Rapid Quantification of Oxidized and Reduced Forms of Glutathione Using Ortho -phthalaldehyde in Cultured Mammalian Cells In Vitro

Rapid Quantification of Oxidized and Reduced Forms of Glutathione Using Ortho -phthalaldehyde in Cultured Mammalian Cells In Vitro

Published on: June 28, 2024

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Area of Science:

Endocrinology
Internal Medicine
Biochemistry

Background:

Graves' disease (GD) is an autoimmune disorder characterized by hyperthyroidism.
Osteopontin (OPN) and oxidative stress are implicated in the pathogenesis of GD.
Antithyroid drugs like methimazole (MTZ) and propylthiouracil (PTU) are standard treatments for GD.

Purpose of the Study:

To compare the efficacy of methimazole (MTZ) and propylthiouracil (PTU) in modulating osteopontin (OPN) levels and oxidative stress markers in patients with Graves' disease.
To evaluate the impact of these treatments on total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI).

Main Methods:

A study involving 60 hyperthyroid Graves' disease patients and 30 healthy controls.
Patients were randomized into two groups: 30 receiving PTU and 30 receiving MTZ.
Blood samples were collected before treatment and three months post-treatment to assess OPN, TAS, TOS, and OSI levels.

Main Results:

Graves' disease patients exhibited significantly higher OPN, TAS, TOS, and OSI levels compared to controls before treatment.
PTU treatment led to a significant reduction in OPN, TOS, and OSI levels, with a significant increase in TAS.
MTZ treatment resulted in a significant decrease in TAS but did not significantly alter OPN, TOS, or OSI levels.

Conclusions:

Propylthiouracil (PTU) demonstrates superior effectiveness compared to methimazole (MTZ) in ameliorating osteopontin levels and reducing oxidative stress in Graves' disease patients.
The findings suggest PTU may offer additional benefits beyond achieving euthyroidism by targeting specific disease-related biomarkers.